[Cellular immunotherapy for brain tumors].
Kikuchi
Tetsuro
T
Department of Oncology, Institute of DNA Medicine, Jikei University.
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D017951:Antigen Presentation; D018122:B7-1 Antigen; D051940:B7-2 Antigen; D001932:Brain Neoplasms / Q000276:immunology / Q000628:therapy*; D018106:CD28 Antigens; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology; D064987:Cell- and Tissue-Based Therapy; D016207:Cytokines / Q000235:genetics; D018014:Gene Transfer Techniques; D015316:Genetic Therapy / Q000379:methods; D015395:Histocompatibility Antigens Class I / Q000276:immunology; D000949:Histocompatibility Antigens Class II / Q000276:immunology; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use; D007167:Immunotherapy / Q000379:methods*; D016219:Immunotherapy, Adoptive; D008213:Lymphocyte Activation; D017410:Practice Guidelines as Topic
D000911:Antibodies, Monoclonal; D018122:B7-1 Antigen; D051940:B7-2 Antigen; D018106:CD28 Antigens; D016207:Cytokines; D015395:Histocompatibility Antigens Class I; D000949:Histocompatibility Antigens Class II; D007155:Immunologic Factors